Bioprosthetic Total Artificial Heart in Autoregulated Mode Is Biologically Hemocompatible: Insights for Multimers of von Willebrand Factor.

Adult Heart, Artificial / adverse effects Hemoglobins Hemolysis Humans von Willebrand Diseases von Willebrand Factor
blood volume heart failure heart transplantation hemodynamics plasma

Journal

Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803

Informations de publication

Date de publication:
04 2022
Historique:
pubmed: 11 2 2022
medline: 6 5 2022
entrez: 10 2 2022
Statut: ppublish

Résumé

Carmat bioprosthetic total artificial heart (Aeson; A-TAH) is a pulsatile and autoregulated device. The aim of this study is to evaluate level of hemolysis potential acquired von Willebrand syndrome after A-TAH implantation. We examined the presence of hemolysis and acquired von Willebrand syndrome in adult patients receiving A-TAH support (n=10) during their whole clinical follow-up in comparison with control subjects and adult patients receiving Heartmate II or Heartmate III support. We also performed a fluid structure interaction model coupled with computational fluid dynamics simulation to evaluate the A-TAH resulting shear stress and its distribution in the blood volume. The cumulative duration of A-TAH support was 2087 days. A-TAH implantation did not affect plasma free hemoglobin over time, and there was no association between plasma free hemoglobin and cardiac output or beat rate. For VWF (von Willebrand factor) evaluation, A-TAH implantation did not modify multimers profile of VWF in contrast to Heartmate II and Heartmate III. Furthermore, fluid structure interaction coupled with computational fluid dynamics showed a gradually increase of blood damage according to increase of cardiac output ( We demonstrated that A-TAH does not cause hemolysis or AWVS. However, relationship between HMWM and cardiac output depending flow confirms relevance of VWF as a biological sensor of blood flow, even in normal range.

Sections du résumé

BACKGROUND
Carmat bioprosthetic total artificial heart (Aeson; A-TAH) is a pulsatile and autoregulated device. The aim of this study is to evaluate level of hemolysis potential acquired von Willebrand syndrome after A-TAH implantation.
METHODS
We examined the presence of hemolysis and acquired von Willebrand syndrome in adult patients receiving A-TAH support (n=10) during their whole clinical follow-up in comparison with control subjects and adult patients receiving Heartmate II or Heartmate III support. We also performed a fluid structure interaction model coupled with computational fluid dynamics simulation to evaluate the A-TAH resulting shear stress and its distribution in the blood volume.
RESULTS
The cumulative duration of A-TAH support was 2087 days. A-TAH implantation did not affect plasma free hemoglobin over time, and there was no association between plasma free hemoglobin and cardiac output or beat rate. For VWF (von Willebrand factor) evaluation, A-TAH implantation did not modify multimers profile of VWF in contrast to Heartmate II and Heartmate III. Furthermore, fluid structure interaction coupled with computational fluid dynamics showed a gradually increase of blood damage according to increase of cardiac output (
CONCLUSIONS
We demonstrated that A-TAH does not cause hemolysis or AWVS. However, relationship between HMWM and cardiac output depending flow confirms relevance of VWF as a biological sensor of blood flow, even in normal range.

Identifiants

DOI: 10.1161/ATVBAHA.121.316833 PMID: 35139659
pubmed: 35139659
doi: 10.1161/ATVBAHA.121.316833
doi:

Substances chimiques

Hemoglobins 0
von Willebrand Factor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

470-480

Commentaires et corrections

Type : CommentIn

Auteurs

Bastien Poitier (B)

Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France (B.P., A.C., C.L.).
Cardiac Surgery Department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (B.P., A.C., C.L.).
Carmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.).

Richard Chocron (R)

Université de Paris, PARCC, INSERM, F-75015 Paris, France, Emergency department, AP-HP, Georges Pompidou European Hospital, France (R.C.).
ORCID: 0000-0002-5498-8937

Christophe Peronino (C)

Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).

Aurélien Philippe (A)

Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).

Yuri Pya (Y)

National Research Cardiac, Surgery Center, Nur-Sultan, Kazakhstan (Y.P., M.B.).

Nadia Rivet (N)

Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).

Ulysse Richez (U)

Carmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.).
Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).

Mahabbat Bekbossynova (M)

National Research Cardiac, Surgery Center, Nur-Sultan, Kazakhstan (Y.P., M.B.).
ORCID: 0000-0003-2834-617X

Nicolas Gendron (N)

Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).
ORCID: 0000-0003-4852-4738

Marc Grimmé (M)

Carmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.).
ORCID: 0000-0001-5525-4858

Marie Cécile Bories (MC)

Université de Paris, Cardiac Surgery Department, AP-HP, Georges Pompidou European Hospital, France (M.C.B.).

Julie Brichet (J)

Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).

Antoine Capel (A)

Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France (B.P., A.C., C.L.).
Cardiac Surgery Department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (B.P., A.C., C.L.).

Jeanne Rancic (J)

Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).

Benoit Vedie (B)

AP-HP, Biochemistry Department, Georges Pompidou European Hospital, France (B.V.).
ORCID: 0000-0003-1167-5356

Jean Christian Roussel (JC)

Cardiac and thoracic Surgery Department, CHU de Nantes, hôpital Nord Laënnec, boulevard Jacques-Monod, France (J.C.R.).
ORCID: 0000-0003-3928-6977

Anne-Sophie Jannot (AS)

Department of Bioinformatics, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France (A.-S.J.).

Piet Jansen (P)

Alain Carpentier (A)

Carmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.).

Peter Ivak (P)

Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.I., I.N.).

Christian Latremouille (C)

Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France (B.P., A.C., C.L.).
Cardiac Surgery Department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (B.P., A.C., C.L.).

Ivan Netuka (I)

Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.I., I.N.).

David M Smadja (DM)

Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.).
ORCID: 0000-0001-7731-9202

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Bioprosthetic Total Artificial Heart in...
questionsmedicales.fr › Équipement et fournitures › Équipement chirurgical › Organes artificiels › Coeur artificiel › Bioprosthetic Total Artificial Heart in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Hémoprotéines › Globines › Hémoglobines › Bioprosthetic Total Artificial Heart in...
questionsmedicales.fr › Phénomènes du système immunitaire › Réaction antigène-anticorps › Hémolyse › Bioprosthetic Total Artificial Heart in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Bioprosthetic Total Artificial Heart in...
questionsmedicales.fr › Malformations et maladies congénitales, héréditaires et néonatales › Maladies génétiques congénitales › Troubles héréditaires de la coagulation sanguine › Maladies de von Willebrand › Bioprosthetic Total Artificial Heart in...
questionsmedicales.fr › Facteurs biologiques › Facteurs de la coagulation sanguine › Facteur de von Willebrand › Bioprosthetic Total Artificial Heart in...